Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

PROTECT-HER KIT to Improve HPV Self-Sampling Uptake Among Women in Selangor (PROTECTHER KIT)

13. november 2026 oppdatert av: Fairuz Alia Rafiai, Universiti Teknologi Mara

Development, Validation, and Evaluation of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) on HPV Self-Sampling Uptake Among the KOSPEN Community in Selangor: A Cluster Randomised Controlled Trial

This study aims to evaluate the effectiveness of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) in improving human papillomavirus (HPV) self-sampling uptake among eligible women in KOSPEN communities in Selangor, Malaysia. The study uses a two-arm, parallel cluster randomised controlled trial involving 106 women aged 30-65 years across eight KOSPEN localities. Localities will be randomly allocated to receive either the PROTECT-HER KIT educational intervention or standard Ministry of Health educational materials. The primary outcome is HPV self-sampling uptake assessed at one and two months following the intervention. Secondary outcomes include cervical cancer awareness and protection motivation measured at baseline, one month, and two months.

Studieoversikt

Detaljert beskrivelse

The goal of this cluster randomised controlled trial is to evaluate the effectiveness of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) in improving human papillomavirus (HPV) self-sampling uptake, cervical cancer awareness, and protection motivation among eligible women in the Komuniti Sihat Pembina Negara (KOSPEN) communities in Selangor, Malaysia. The PROTECT-HER KIT is a newly developed health education package designed to improve women's knowledge, perceived risk, confidence, and motivation to undergo HPV self-sampling for cervical cancer screening.

The main questions this study aims to answer are:

Will the PROTECT-HER KIT increase HPV self-sampling uptake among eligible women in KOSPEN communities in Selangor?

Will the PROTECT-HER KIT improve cervical cancer awareness among participants?

Will the PROTECT-HER KIT improve protection motivation, including perceived severity, perceived vulnerability, response efficacy, self-efficacy, and perceived response costs related to HPV self-sampling?

To evaluate the effectiveness of the PROTECT-HER KIT, researchers will conduct a two-arm cluster randomised controlled trial involving eight KOSPEN localities in Selangor. The localities will be randomly assigned to either the intervention group or the control group. The intervention group will receive the PROTECT-HER KIT, comprising a structured face-to-face health education session using flipcharts, video demonstrations, facilitated discussions, and practical guidance on HPV self-sampling, followed by WhatsApp reinforcement messages and action-planning reminders. The control group will receive standard cervical cancer prevention educational materials from the Ministry of Health Malaysia.

Participants will:

Complete a baseline questionnaire (T0) assessing their sociodemographic characteristics, cervical cancer awareness, protection motivation, and previous cervical cancer screening history.

Receive either the PROTECT-HER KIT educational intervention or standard Ministry of Health educational materials, depending on the KOSPEN locality to which they belong.

Complete follow-up questionnaires at approximately one month (T1) and two months (T2) after the educational intervention to assess changes in cervical cancer awareness, protection motivation, and HPV self-sampling uptake.

Report whether they have undergone HPV self-sampling for cervical cancer screening during the follow-up period.

The findings will help determine whether a theory-based, community-delivered health education intervention can improve HPV self-sampling uptake and support cervical cancer prevention efforts in Malaysia.

Studietype

Intervensjonell

Registrering (Antatt)

106

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Putrajaya
      • Petaling Jaya, Putrajaya, Malaysia, 40000
        • Pejabat Kesihatan Daerah Petaling
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

30 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  1. Malaysian women aged 30-65 years.
  2. Residing in a participating KOSPEN locality in Selangor.
  3. Able to read and understand Malay.
  4. Never screened or overdue for cervical cancer screening according to current Malaysian guidelines.
  5. Own a smartphone with WhatsApp.

Exclusion Criteria:

  1. Physical or mental impairment preventing participation in study procedures.
  2. Declines to participate or provide informed consent.
  3. Diagnosed cervical cancer or precancerous cervical disease.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Screening
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: PROTECT-HER KIT

Participants will receive a structured, approximately 90-minute face-to-face educational session incorporating four modules: cervical cancer and HPV risk education, HPV self-sampling procedures and skills, emotional and practical barriers, and action planning. Educational materials include flipcharts, video demonstrations, facilitated discussions and standardised WhatsApp reinforcement and reminders.

Participants allocated to the intervention group will receive the PROTECT-HER KIT, a structured educational intervention based on Protection Motivation Theory (PMT) to improve cervical cancer awareness, protection motivation, and HPV self-sampling uptake. The intervention consists of a single approximately 90-minute, face-to-face small-group educational session delivered by the principal researcher using flipcharts, a video demonstration, facilitated discussions, and practical guidance on HPV self-sampling. The educational content addresses perceived severity, perceived vulnerability, response efficacy, self-efficacy, and perceived response costs related to cervical cancer screening. Standardised WhatsApp reinforcement messages and action-planning reminders will be provided following the session to encourage HPV self-sampling uptake. The intervention will be delivered after completion of the baseline assessment (T0).

Aktiv komparator: Standard Ministry of Health Education

Participants will receive a one-off distribution of existing Ministry of Health educational materials containing general information on women's health and cervical cancer prevention. Participants will continue to have access to routine cervical cancer screening services.

Participants allocated to the control group will receive a one-off distribution of standard health educational materials sourced from the Ministry of Health Malaysia. These materials provide general information on women's health, cervical cancer prevention, and cervical cancer screening. Unlike the intervention group, participants will not receive the structured PROTECT-HER KIT educational session or standardised WhatsApp reinforcement messages. The educational materials will be distributed once following completion of the baseline assessment (T0). Participants will continue to have access to routine cervical cancer screening services.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Secondary: Cervical cancer awareness
Tidsramme: Baseline, 1 and 2 months

Cervical Cancer Awareness Scale (Cx-CAS), 15 items

Baseline, 1 and 2 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Secondary: Cervical cancer awareness
Tidsramme: Baseline, 1 and 2 months

Cervical Cancer Awareness Scale (Cx-CAS), 15 items

Baseline, 1 and 2 months
Secondary: Protection motivation
Tidsramme: Baseline, 1 and 2 months

Adapted Malay PMT questionnaire, 24 items

Baseline, 1 and 2 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. mars 2027

Primær fullføring (Antatt)

30. juni 2027

Studiet fullført (Antatt)

30. juni 2027

Datoer for studieregistrering

Først innsendt

9. november 2026

Først innsendt som oppfylte QC-kriteriene

13. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data (IPD) will not be made publicly available due to the sensitive nature of the information collected, including cervical cancer screening history, HPV self-sampling uptake, and health-related perceptions. Data confidentiality and participant privacy will be maintained in accordance with the approved study protocol, institutional ethical requirements, and applicable data protection regulations. Study findings will be disseminated through scientific publications and presentations in aggregate form without identifying individual participants.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere